Receptor Interactions of Abbott-81988, A Highly Potent, Non-Peptide Angiotensin-II Antagonist Selective for Type-1 Receptors

References

• Pals D. T., Masucci F. D., Denning G. S., Jr., Sipos F., Fessler D. C. Role of the pressor action of angiotensin II in experimental hypertension. Circ. Res. 1971; 29: 673–681
   PubMed Web of Science ®Google Scholar
• Nishikawa K., Shibouta Y., Inada Y., Terashita Z., Kawazoe K., Furukawa Y. Nonpeptide angiotensin II receptor antagonists: pharmacological studies on imidazoleacetic acid derivatives. J. Takeda Res. Lab 1991; 50: 75–98
   Google Scholar
• Wong P. C., Chiu A. T., Duncia J. V., Herblin W. F., Smith R. D., Timmermans P. B. M. W. M. Angiotensin II receptor antagonists and receptor subtypes. Trends in Endocrin. Metab. 1992; 3: 211–217
   PubMed Web of Science ®Google Scholar
• Song K., Zhuo J., Allen A. M., Paxinos G., Mendelsohn F. A. O. Angiotensin‐II receptor subtypes in rat brain and peripheral tissues. Cardiology 1992; 79(Suppl 1)45–54
   Google Scholar
• Bumpus F. M., Catt K. J., Chiu A. T., Degasparo M., Goodfriend T., Husain A., Peach M. J., Taylor D. G., Jr., Timmermans P. B. M. W. M. Nomenclature for angiotensin receptors: a report of the nomenclature committee of the council for high blood pressure research. Hypertension 1992; 17: 720–721
   Google Scholar
• De B., Winn M., Zydowsky T. M., Kerkman D. J., DeBernardis J. F., Lee J., Buckner S., Warner R., Brune M., Hancock A., Opgenorth T., Marsh K. Discovery of a novel class of orally active, nonpeptide angiotensin‐II antagonists. J. Med. Chem. 1992; 35: 3714–3717
   PubMed Web of Science ®Google Scholar
• Chiu A. T., Carini D. J., Johnson A. L., McCall D. E., Price W. A., Thoolen M. J. M. C., Wong P. C., Taber R. I., Timmermans P. B. M. W. M. Non‐peptide angiotensin‐II receptor antagonists. II. Pharmacology of S‐8308. Eur. J. Pharmacol. 1988; 157: 13–21
   PubMed Web of Science ®Google Scholar
• DeLean A., Munson P. J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose‐response curves. Am. J. Physiol. 1980; 235: E97–E102
   Google Scholar
• Schild H. O. pA, A new scale for the measurement of drug antagonism. Br. J. Pharmacol. 1947; 2: 189–206
   PubMed Web of Science ®Google Scholar
• Fluharty S. J., Reagen L. P. Characterization of binding sites for the angiotensin II antagonist 125l‐[SARC1ILE8]‐angiotensin II on murine neuroblastoma N1E‐115 cells. J. Neurochem. 1989; 52: 1393–1400
   PubMedGoogle Scholar
• Neville D. M., Jr. Isolation of an organ specific protein antigen from cell‐surface membrane of rat liver. Biochem. Biophys. Acta. 1968; 154: 540–552
   PubMed Web of Science ®Google Scholar
• DeBernardis J. F., Kerkman D. J., Winn M., Bush E. N., Arendsen D. L., McClellan W. J., Kyncl J. J., Basha F. Z. Conformationally defined adrenergic agents. 1, Design and synthesis of novel alpha‐2 selective adrenergic agents: Electrostatic repulsion based conformation prototypes. J. Med. Chem. 1985; 28: 1398–1404
   PubMedGoogle Scholar
• Hancock A. A., Delean A. L., Lefkowitz R. J. Quantitative resolution of beta‐adrenergic subtypes by selective ligand binding: application of a computer model‐fitting technique. Mol. Pharmacol. 1979; 16: 1–9
   PubMed Web of Science ®Google Scholar
• DeLean A. L., Ong H., Gutkowska J., Schiller P. W., McNicoll N. Evidence for agonist‐induced interaction of angiotensin receptor with a guanine nucleotide‐binding protein in bovine adrenal zona glomerulosa. Mol. Pharmacol. 1984; 26: 498–508
   PubMedGoogle Scholar
• Gangiano J. L., Rodriguez‐Sargent C., Martinez‐Maldonado M. Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. J. Pharmacol. Exp. Ther. 1979; 208: 310–313
   PubMedGoogle Scholar
• Wong P. C., Price W. A., Chiu A. T., Duncia J. V., Carini D. J., Wexler R. R., Johnson A. L., Timmermans P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 1990; 252: 726–732
   PubMed Web of Science ®Google Scholar
• Scanlon M. N., Moore G. J. Classification of angiotensin receptors in rat isolated uterus, portal vein, and aorta using a slowly dissociating antagonist [Sar1 lle8]ANG II for receptor blockade, J. Pharmacol. Meth. 1988; 20: 207–224
   Google Scholar
• Hancock A. A., Buckner S. A., Lee J. Y., Brune M., Morse P. A., Oheim K., Warner R. B., Winn M., Zydowsky T. M., De B., Kerkman D. J., DeBernardis J. F. Pharmacological characterization of Abbott‐81282, a novel, non‐peptide angiotensin‐II antagonist selective for type‐1 receptors. Life Sciences 1993; 53: 929–937
   PubMedGoogle Scholar
• Wong P. C., Price W. A., Jr., Chiu A. T., Duncia J. V., Carini D. J., Wexler R. R., Johnson A. L., Timmermans P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 1990; 255: 211–217
   PubMed Web of Science ®Google Scholar
• Chang R. S. L., Siegl P. K. S., Clineschmidt B. V., Mantlo N. B., Chakravarty P. K., Greenlee W. J., Patchett A. A., Lotti V. J. In vitro pharmacology of L‐158,809, a highly potent and selective angiotensin II receptor antagonist. J. Pharm. Exp. Ther. 1992; 262: 133–138
   PubMedGoogle Scholar
• Chiu A. T., McCall D. E., Price W. A., Wong P. C., Carini D. J., Duncia J. V., Wexler R. R., Yoo S. E., Johnson A. L., Timmermans P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J. Pharm. Exp. Ther. 1990; 252: 711–718
   PubMed Web of Science ®Google Scholar
• Van Rossum J. Cumulative dose‐response curves. II. Technique for the making of dose‐response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. Ther. 1963; 143: 299–330
   PubMedGoogle Scholar
• Hancock A. A., Surber B., Rotert G., Thomas S., Tasker A., Sorensen B., Vodenlich A., Opgenorth T., Kerkman D., DeBernardis J. F. [3H]‐A‐81988, A potent, selective, competitive antagonist radioligand for angiotensin‐II type 1 receptors (AT1 R). The FASEB Journal 1993; 7: A246
   Google Scholar
• Casteilion A. W., Fulton R. W. Preclinical pharmacology of saralasin. Kidney International 1979; 15: S11–S19
   Google Scholar
• Oheim K., Morse P., Buckner S. A., Milicic I., Hancock A. A., Lee J. Y., Marsh K. C., Bauch J., Winn M., De B., Zydowsky T. M., Kerkman D. J., DeBernardis J. F. Abbott(A)‐81988: A potent, competitive nonpeptide antagonist at the angiotensin‐II‐1 Receptor (AT1R) with advantageous pharmacokinetics. FASEB Journal 1993; 7: A245
   Google Scholar
• Brune M. E., Lee J. Y., Warner R. B., Winn M., De B., Zydowsky T. M., Opgenorth T. J., Kerkman D. J., DeBernardis J. F. Abbott (A)‐81988, a nonpeptide angiotensin II (All) antagonist: Comparative antihypertensive effects in renal artery‐ligated (RAL) rat and safety profile. FASEB J. 1993; 7: A246
   Google Scholar
• Winn M., De B., Zydowsky T. M., Altenbach R., Basha F., Boyd S., Brune M., Buckner S., Crowell D., Drizin I., Hancock A., Jae H. S., Kester J., Lee J., Mantei R., Marsh K., Novosad E., Oheim K., Rosenberg S., Shiosaki K., Sorensen B., Spina K., Sullivan G., Tasker A., von Geldern T., Warner R., Opgenorth T., Kerkman D., DeBernardis J. 2‐Alkylamino nicotinic acid and analogs–potent angiotensin II antagonists. J. Med Chem. 1993; 36: 2676–2688
   PubMedGoogle Scholar